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Myelodysplastic syndrome (MDS) is characterized by an ineffective hematopoiesis 
with production of aberrant clones and a high cell apoptosis rate in bone marrow 
(BM). Macrophages are in charge of phagocytosis. Innate Immune cells and specific 
T cells are in charge of immunosurveillance. Little is known on BM cell recruitment and 
activity as BM aspirate is frequently contaminated with peripheral blood. But evidences 
suggest an active role of immune cells in protection against MDS and secondary 
leukemia. BM CD8+ CD28− CD57+ T cells are directly cytotoxic and have a distinct 
cytokine signature in MDS, producing TNF-α, IL-6, CCL3, CCL4, IL-1RA, TNFα, FAS-
L, TRAIL, and so on. These tools promote apoptosis of aberrant cells. On the other 
hand, they also increase MDS-related cytopenia and myelofibrosis together with TGFβ. 
IL-32 produced by stromal cells amplifies NK cytotoxicity but also the vicious circle of 
TNFα production. Myeloid-derived suppressing cells (MDSC) are increased in MDS and 
have ambiguous role in protection/progression of the diseases. CD33 is expressed on 
hematopoietic stem cells on MDS and might be a potential target for biotherapy. MDS 
also has impact on immunity and can favor chronic inflammation and emergence of 
autoimmune disorders. BM is the site of hematopoiesis and thus contains a complex 
population of cells at different stages of differentiation from stem cells and early engaged 
precursors up to almost mature cells of each lineage including erythrocytes, megakary-
ocytes, myelo-monocytic cells (monocyte/macrophage and granulocytes), NK cells, and 
B cells. Monocytes and B cell finalize their maturation in peripheral tissues or lymph 
nodes after migration through the blood. On the other hand, T cells develop in thymus 
and are present in BM only as mature cells, just like other well vascularized tissues. BM 
precursors have a strong proliferative capacity, which is usually associated with a high risk 
for genetic errors, cell dysfunction, and consequent cell death. Abnormal cells are prone 
to destruction through spontaneous apoptosis or because of the immunosurveillance 
that needs to stay highly vigilant. High rates of proliferation or differentiation failures lead 
to a high rate of cell death and massive release of debris to be captured and destroyed 
(1). Numerous macrophages reside in BM in charge of home-keeping. They have a high 
capacity of phagocytosis required for clearing all these debris.
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Abbreviations: AAM, alternatively activated macrophages; AML, acute myeloid leukemia; BM, bone marrow; CFU-GM, 
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ESCCA, European Society for Clinical Cell Analysis; FCM, flow cytometry; FITC, fluorescein isothiocyanate; FSC, forward 
scatter; MdFI, median fluorescence intensity; MDS, myelodysplastic syndrome; MDSC, myeloid derived suppressive cells; 
MRD, minimal residual disease; PAMP, pathogen-associated molecular patterns; PB, peripheral blood; PE, phycoerythrin; 
ROS, reactive oxygen species; SSC, side scatter; TLR, toll like receptors; WHO, World Health Organization.
FiGURe 1 | Schematic representation of normal hematopoiesis. Normal hematopoietic stem cell (1) self-renew with the close support of stroma (2) and 
growth factors (3) on the fibrotic matrix (4). A low proportion of cells fails during the proliferation and differentiation processes. Abnormal cells are destroyed by 
apoptosis or under immune surveillance, being phagocytized by resident macrophages (5).
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iMMUniTY in BOne MARROw
The immune effectors penetrates into the BM hematopoietic 
niche with difficulty, and this is probably the reason for which 
the BM is a predilection site for the metastases from solid tumors 
where they like to hide and develop (Figure 1) (2). BM bacterial 
infections are rare. This may be because the BM is deep and bac-
teria probably have to go through multiple barriers to reach it. But 
we cannot exclude a role of the immune system in the surveillance 
and occasional protection against any infection event. In any case, 
this activity is difficult to evaluate in  situ. Indeed, BM is easily 
analyzed, specially with the help of flow cytometry, but BM sam-
pling requires a deep aspiration that is inevitably contaminated 
by peripheral blood. BM biopsy only gives precious information 
on anatomical distribution but it is limited in qualitative and 
quantitative characterization of resident cells.
In general, immunosurveillance plays an important role in 
maintaining homeostasis and eliminating aberrant clones (3). 
Deficiencies in immunosurveillance raise the risk of develop-
ing tumors. In the same line, some therapeutic strategies have 
been designed to boost the immunosurveillance for preventing 
relapse and eventually cure cancer (4). T cells and type I Innate 
Lymphoid cells (ILC) are the major effectors of specific or innate 
cytotoxicity. ICL type I includes NK cells. Macrophages closely 
cooperate with lymphocytes through the production of cytokines 
and chemokines. Effector lymphocytes are mobile in the blood 
stream or reside quietly in the lymphoid tissues, far from BM. 
Lymphocytes are only recruited in the tissues if needed, driven 
by the gradient of chemokines. For that purpose, they express 
chemokine receptors and adhesion molecules. A few chemokines 
receptors or adhesion molecules have some tissue specificity 
such as CCR7, alpha4-beta7, or CD103 and CLA for Lymph 
FiGURe 2 | Dysplastic hematopoiesis. In myelodysplastic settings, the stem 
cell function is disturbed by several abnormal conditions such as local 
inflammation (1) defect in stromal support (2), inappropriate growth factor 
production (3), myelofibrosis (4), that are conducive to an increased cell renewal 
(5), and, subsequently, to higher risk of failure and mutations. The production of 
Alarmins induce a pro-inflammatory vicious circle loop, a cytotoxic immune 
reaction, and impair the immunomodulatory process. Differentiation in lineages 
is reduced and eventually aberrant. In addition, the higher level of mutations is 
responsible for higher home keeping activity with exhaustion.
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node, mucosae or skin, respectively, while CXCR3 guide cells 
to inflamed tissues (5). Analyzing the expression of chemokine 
receptors is a good tool to identify cells specifically recruited in 
the BM (6) but, unfortunately, no homing receptor specific for 
BM is identified yet.
Under activation, lymphocytes produce cytokines and build 
up complex crosstalks between all effectors. Cytokines such as 
IL-2, IFN-γ, IL-17, TNFα promote inflammation and cytotoxicity 
while IL-10 or TGFβ downregulated the immune response and 
promote tissue healing. These mediators are required to set up a 
good immunosurveillance but are poorly discriminant and can 
incidentally help pathological cell growth and/or downregulate 
immune cells. For example, TGFβ promotes healing but is a strong 
inducer of Regulatory T cells (Treg). Similarly, Myeloid-derived 
suppressing cells (MDSC) support progenitor proliferation, partly 
through CD33 receptor (7) but can also support tumor growth 
by producing growth factors or angiogenic factors (8). MDSCs 
express CD45, CD33, and CD11b+ and derive from monocytes 
(CD14+ CD15−) or granulocytes (CD14− CD15+) (9). As a matter 
of fact, granulocyte-derived MDSC was reported to be increased 
in BM and PB of multiple myeloma (9, 10) and can promote the 
tumor growth (11) raising interesting therapeutic potentials (12).
FeeDinG ACTiviTY OF THe STROMA  
in nORMAL BOne MARROw
The process of hematopoiesis is closely related to its micro-envi-
ronment that includes extracellular matrix, mesenchymal cells, 
macrophages, etc. The stromal cells are supporting the survival 
and proliferation of progenitor cells (13, 14). Macrophages are 
also contributing a lot in this support through direct contact 
with progenitors or by producing growth and angiogenic factors. 
Notably, TNFα can promote proliferation of hematopoietic pro-
genitors (15). Again, this support is not discriminant and helps 
healthy and pathological clones as well, but pathological clones 
frequently acquire proliferative advantages over normal cells.
Myelodysplastic syndrome (MDS) is a heterogeneous group 
of acquired clonal disorders of stem cell, altering hematopoiesis 
efficiency. Stem cell renewal is increased raising the risks for 
mutations and cell aberrancies, and MSD is associated with a 
higher risk for the development of Acute Myeloblastic Leukemia 
(AML). The efficiency of cell differentiation is reduced leading 
to cytopenia that concerns variably one or several lineages. The 
microenvironment is progressively damaged and fails in stromal 
support but induces progressive myelofibrosis (2, 16). This prolif-
eration and maturation disorders are associated with an increased 
rate of cell death by apoptosis or pyroptosis. The cause(s) of MDS 
remains unknown. Few genetic or environmental conditions 
promote MDS (17).
POSSiBLe ROLe OF 
MiCROenviROnMenT in MDS
The MDS primary disorder is generally believed to come from 
the stem cell. However, stem cell behavior is closely related to 
the stroma, and stromal disorders have also been shown in MDS, 
even when stromal cells are cultivated in absence of pathologi-
cal hematopoietic cells. This suggests that the primary disorder 
could also start with stromal cells (18). However, the micro-
environment is certainly disturbed by the pathological clone (19) 
and particular mesenchymal cells could also be actively recruited 
by aberrant cells through the production of CCL25 as it has been 
described in myeloma (20). At the end, experts conclude that 
the cooperation effect is most probably “mutual and reciprocal” 
(21). Still remains the possibility that pathological clones and its 
microenvironment are both victims of a same extrinsic cause that 
could be infection or toxic agent not yet identified.
iMMUne DiSORDeRS ASSOCiATeD wiTH 
MYeLODYSPLASTiC BOne MARROw
Despite no extrinsic agent has been implicate, there is evidence 
of an inflammation process in MDS BM (Figure 2). Numerous 
studies report there are high productions of TNFα, IFNγ, IL-1α; 
IL-6, IL-17, TGFβ, using different techniques such as immuno-
histology, BM dosages, functional analyses, and even in periph-
eral blood dosages (22–32). These cytokines can be produced 
not only by resident macrophages and attracted lymphocytes 
but also by stromal cells and stem cells. Macrophages are highly 
engaged in clearing all debris from aborted differentiation of 
hematopoietic cells (33, 34). Cell damages produce Damage-
Associated Molecular Patterns (DAMPs) that are, together 
with pathogen-associated molecular patterns (PAMPs), strong 
4Lambert et al. Immunity in BM and MDS
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ligands for Pattern-Recognition Receptors (PRRs). Among the 
PRRs, the Toll Like Receptor 4 (TLR4) is overexpressed not 
only by MDS macrophages but also by stem cells and stromal 
cells (35–37). Among DAMPS, alarmins such as the S100A9 are 
produced in MDS, and S100A9 was shown to promote pyroptosis 
and apoptosis (7, 38). A polyclonal T cell infiltrate has also been 
demonstrated in MDS BM (39), specially CD4+ T cells producing 
IFNγ (40). T cell turnover (41) and apoptosis are elevated and 
correlated to the cytokine production (42). Effector, cytotoxic 
(CD8+ CD28− CD57+) T cells are increased in peripheral blood 
of MDS patients (43).
iMMUne ReSPOnSe ACTS  
AGAinST MDS PROGReSSiOn
The pro-apoptotic cytokines can participate in the elimina-
tion of aberrant clones, and progenitors have been shown to 
express TNF family receptors. NK cells are also directly active 
in destroying aberrant cells (44). Finally, aberrant phenotypes 
can induce specific immunity, and T cell infiltrate has been 
observed, specially CD8+ T cells with restricted T cell receptor 
Vbeta diversity. These cells frequently bear an activated profile 
(CD25, CD58) and have a high content of cytotoxic proteins 
(granzyme) as compared to peripheral blood (45). A CD8+ 
T cell proliferation specific for trisomy 8 related aneuploid 
hematopoietic progenitor cells has been reported (46). The 
higher CD8+ T cell count is associated with a lower count of 
regulatory T cells (Treg) in BM (47). BM T cells have a distinct 
functional signature producing high levels of TNF-α, IL-6, 
CCL3, CCL4, and IL-1RA (48). Note that CCL3 is preferen-
tially produced, and its production is associated with a poor 
prognostic as reported for CCL5 in AML (49). These evidences 
strongly suggest that there is an active antigen specific T cell 
response in BM especially in MDS. It is not clear yet if the T cell 
specificity recognize an auto-antigen or a neo-antigen related to 
MDS aberrancies.
DeFeCT in iMMUnO SURveiLLAnCe 
FAvORS MDS
In MDS, NK cell number is usually not reduced as compared to 
healthy donors (50, 51) although it can be low in as much as 20% 
of patients, independently of T lymphopenia. NK deficiency is 
directly related to a MDS with poor prognosis such as refrac-
tory anemia with excess blasts (52). However, a NK functional 
deficiency has been reported with a decrease in their content 
of perforin and granzyme and a defect in production of IFNγ 
(50,  53, 54). The NK functional deficiency is also associated with 
a high risk of MDS (55). IL-32 is produced by several cells under 
stimulation by TNFα or IL-1. NK cells capacity for production 
of IL-32 is reduced in MDS (56) and as well as the expression 
of the NK activating receptor (NKG2D). This reduced capacity 
was associated with the NK functional deficiency (50, 57). The 
MDS patients are frequently old. The NK activity is also declining 
with aging, making the NK deficiency due to the diseases even 
worse (55). Therapeutic strategies forcing NK cells to recognize 
of CD33+ MDS progenitors using bispecific antibodies have been 
proposed (58). On the other hand, IL-2 or IL-12 therapeutic 
 trials have not shown any significant clinical benefit in MDS (53). 
Another ILC, the invariable NKT cells, have also been reported to 
be reduced in MDS (59).
Peripheral Treg are increased in MDS with more than 5% of 
blasts in accordance with the disease progression (27, 45, 60). This 
is even more clear if we consider the effector memory Treg, which 
have higher regulatory activity (61).
Accordingly, some immunodeficiencies favor MDS. The 
“Monomac syndrome” is a sporadic primary immunodeficiency 
due to a GATA2 mutation. It associates severe monocytopenia 
(mean value 10 cells/μL) and possibly B and/or NK and/or den-
dritic cell deficiencies. Monomac syndrome is frequently revealed 
by severe infections with atypical agents like non-tuberculous 
mycobacteria, papillomavirus, or fungi (62). Almost half of these 
patients develop a MDS or an AML. But it is not clear whether 
the evolution to MDS is related to the progenitor abnormalities 
or to the defect of immunodeficiency. In any case, Monomac-
related MDS is not really typical as it shows poorer cellularity and 
prominent reticulin myelofibrosis (63). Few more immunodefi-
ciencies are associated with MDS (64) in which it is difficult to say 
whether the primary genetic mutations or immunodeficiency is 
responsible for MDS emergence.
iMMUne DiSORDeRS PARTiCiPATinG  
TO MDS PHYSiOPATHOLOGY
Few cytokines produced in MDS BM inflammation are strong 
inducer of apoptosis and could aggravate the MDS-related cyto-
penia (Figure 2). TNFα (65) and other related cytokines such as 
TRAIL or FAS-ligand (31, 66) are overproduced in MDS. The 
dosage of TNFα is correlated with the severity of cytopenia (19). 
These pro-apoptotic cytokines can also induce damages to the 
normal progenitors (67, 68) and differentiated cells. Indeed, the 
overall, neutralization of these TNF-related cytokines was shown 
to improve hematopoiesis (42, 66), and MDS has been reported 
in TNFα overproducing transgenic mice (69). Pro-cytotoxic 
CD4+ T cell also has collateral cytotoxic effects participating 
into the cytopenia. These effects could be partially reduced with 
treatment (Cyclosporin A) that reduces Th1 activity (40) and 
cell turnover (41). The TGFβ over production has been related 
to myelofibrosis in MDS and is associated with poor prognosis 
(7, 70, 71).
In MDS, MDSCs was reported to be increased too and to pro-
duce pro-cytotoxic cytokines (72). MDSC could also have direct 
suppressive action on stem cell throughout the CD33 binding (72).
MDS CAn iMPAiR THe  
iMMUne ReSPOnSe
Myelodysplastic syndrome induces immunological disorders 
especially on the monocytic and myelocytic lineages partly due to 
an inadequate production of cytokines. Maturation disorder and 
high apoptosis rate are responsible for phagocytosis exhaustion 
(73). Peripheral cytopenia is frequent except for NK cells (74). 
FiGURe 3 | Ambiguous role of immunity in MDS. Each bone marrow 
component can have actions either good, supporting hematopoiesis and 
homekeeping in homeostasia, or bad: cytopenia, myelofibrosis, and 
inflammation in dysplasia.
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The numbers of B cells or their precursors are strongly reduced 
but B cell dysplasia and defect in immunoglobulin production is 
not considered as a major issue in MDS (75). Peripheral T cells are 
disturbed too with a skewing of its Vbeta repertoire (45). T cells 
have preferentially the pro-inflammatory profiles Th22 and Th17, 
at least at an advanced stage of the disease (27).
Myelodysplastic syndrome can be associated with an increased 
risk for auto-immunity (76) which can, in return, participate in 
the cytopenia. Autoimmune antibodies against erythrocytes 
have been shown in aplastic anemia (77) beside auto-antibodies 
against MDS neo-antigens due to genetic mutations (78). T cell 
auto-reactivity can also play a role in cytopenia and could be 
partly responsible for the reduction of Vβ repertoire (45). A few 
cases of Lymphoproliferative syndrome associated with MDS has 
also been described (79).
In conclusion (Figure  3), there are many evidences that 
immunity plays a role in MDS. However this role is complex and 
ambiguous. An immunity is expected to prevent or delay the emer-
gence of pathological clones through innate antitumor activity or 
specific recognition of neo-antigens but it is most probable the 
MDS clones must find a way to escape the immunosurveillance 
as solid tumors do. An inflammatory status in BM can be a cause 
of consequence of the disease. Chronic inflammation could sup-
port immunity but also has systemic effect worsening a metabolic 
syndrome. Exhaustion and immunodeficiencies can favor MDS 
and AML. On the other hand, the pathological clones manage to 
take over the immune system by producing immuno-modulatory 
cytokines (IL-4, IL-10, and TGFβ) and growth factors (VEGF, 
TNFα, thrombopoietin, etc.) and modulating Treg cell activity. 
The pro/con Immune activity is certainly variable according to 
the stage of the disease. At the stage of clinical expression, MDS 
certainly is already winning against the immunosurveillance. 
Finally, the immune system itself can suffer from MDS progres-
sion due to central cytopenia, Treg accumulation, exhaustion of 
phagocytosis and cytotoxicity, repertoire skewing and possibly 
autoimmune disorders.
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